WebNov 1, 2024 · • LIBRA trial designed to support registration in China• Topline results expected in the fourth quarter of 2024 SHANGHAI and PRINCETON, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- LianBio (Nasdaq ... WebMar 27, 2024 · LianBio received a $20.0 million upfront payment, which was released as part of previously restricted cash paid to LianBio by Pfizer in 2024 pursuant to the Pfizer strategic collaboration agreement. LianBio is eligible to receive up to $135.0 million in potential development and sales milestones.

LianBio (LIAN) Stock Price, Quote & News - Stock Analysis

WebDec 19, 2024 · SHANGHAI, China and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Pfizer opted in to the right to develop and … WebDec 21, 2024 · SHANGHAI, China and PRINCETON, N.J., Dec. 21, 2024 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to … kobe shower pic

GlobeNewswire Notified

WebMar 27, 2024 · LianBio received a $20.0 million upfront payment, which was released as part of previously restricted cash paid to LianBio by Pfizer in 2024 pursuant to the Pfizer … WebLianBio to Continue Development of Camzyos in China and Other Asian Territories. SHANGHAI and PRINCETON, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- LianBio’s (Nasdaq: LIAN) partner, Bristol Myers Squibb, announced yesterday that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg … WebGlobeNewswire. Mar-25-23 09:48AM: LianBio (NASDAQ:LIAN) Is In A Good Position To Deliver On Growth Plans. Simply Wall St. Dec-20-22 10:20AM: ... LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other … kobe steak house restaurant redding ca